Bcbl 1

Body cavity-based lymphoma cells (BCBL-1, KSHV⁺/EBV^neg) and a Burkitt’s lymphoma cell line BL-41 (KSHV^neg/EBV^neg) were kindly provided by Dr. Dean Kedes (University of Virginia) and maintained in RPMI 1640 medium (Gibco) with supplements as described previously [9 (link)]. The Burkitt’s lymphoma cell line BJAB (KSHV^neg/EBV^neg), RAMOS (KSHV^neg/EBV^neg), AKATA (KSHV^neg/EBV⁺) were kindly provided by Dr. Erik Flemington (Tulane University) and cultured as described elsewhere [54 (link)]. PEL cell line BC-1 (KSHV⁺/EBV⁺), BC-3 (KSHV⁺/EBV^neg), and BCP-1 (KSHV⁺/EBV^neg) cells were purchased from American Type Culture Collection (ATCC) and maintained in complete RPMI 1640 medium (ATCC) supplemented with 20% FBS. A diffuse large cell lymphoma (DLCL) cell line CRL2631 (KSHV^neg/EBV^neg) was purchased from ATCC and maintained in complete RPMI 1640 medium (ATCC) supplemented with 10% FBS. Primary human umbilical vein endothelial cells (HUVEC) were cultured as described previously [21 (link)]. KSHV infection was verified for all cell lines using immunofluorescence assays for detection of the KSHV latency-associated nuclear antigen (LANA) [9 (link)]. All cells were cultured at 37°C in 5% CO₂. All experiments were carried out using cells harvested at low (<20) passages. Monosodium glutamate (MSG), Sulfasalazine (SASP) and Bay11-7082 were purchased from Sigma.

The PEL cell-line BCBL-1 (KSHV⁺/EBV^neg) and a Burkitt's lymphoma cell line BL-41 (KSHV^neg/EBV^neg) was kindly provided by Dr. Dean Kedes (University of Virginia) and maintained in RPMI 1640 medium (Gibco) with supplements as described previously [42 (link)]. The other PEL cell-lines BC-1 (KSHV⁺/EBV⁺) and BCP-1 (KSHV⁺/EBV^neg) were purchased from American Type Culture Collection (ATCC) and maintained in complete RPMI 1640 medium (ATCC) supplemented with 20% FBS. All cells were cultured at 37°C in 5% CO₂. All experiments were carried out using cells harvested at low (< 20) passages. Sulfasalazine (SASP) and Doxorubicin were purchased from Sigma.